echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Front Immunol: Genetic susceptibility to IL-13 in bullous pemphigoid: a potential target for therapy and a prognostic marker

    Front Immunol: Genetic susceptibility to IL-13 in bullous pemphigoid: a potential target for therapy and a prognostic marker

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bullous pemphigoid (BP) is a chronic autoimmune skin disease with severe itching more common in the elderly
    .


    It is characterized by skin urticaria, erythema, or painful blisters, and circulating autoantibodies against the half-chromosomal molecules BP180 and BP230 are localized in the basement membrane region of the skin and in basal keratinocytes


    Histopathological examination of BP lesions showed subepidermal blebbing, typically with neutrophilic and eosinophilic infiltration
    .


    Although the exact mechanism is unclear, it has been established that autoantibodies against BP180 may trigger BP through three pathways


    Given their importance in BP disease, these cytokines may be promising targets for the development of new, effective therapeutic strategies for BP
    .


    Cytokines play a cytokine function by regulating the expression of cytokine proteins and the release of cytokines, regulating the susceptibility of autoimmune diseases


    In order to investigate the distribution and clinical significance of cytokine gene polymorphisms in Chinese BP patients, we used a retrospective case-control study to investigate the relationship between various cytokine gene polymorphisms and serum cytokine levels, clinical manifestations and prognosis of patients.
    relationship
    .


    Our goal was to identify the key cytokines most associated with BP and to explore the association of patient characteristics with gene polymorphisms of these cytokines


    IL-1a(Rs1800587), IL-1b(rs16944, rs1143627, rs1143634), IL-4(Rs2243250), IL-6(Rs1800795), IL-10(rs1800896, rs1800871, rs1800872), IL-13(rs1800925, rs2000925) ), TNF-a (rs1799964, rs1799964
    .


    Expression of these cytokines in serum was detected


    We found that the serum levels of IL-1 and IL-13 in BP patients were significantly higher than those in controls
    .


    There were significant differences in the nucleotide ratio/genotype/haplotype frequency/haplotype of IL-13, respectively


    BP is associated with IL-13 gene polymorphisms, and the concentration of IL-13 in the blood of BP patients is increased
    .


    Our results support that IL-13 is involved in the pathogenesis of BP, suggesting that IL-13 may be a potential target and prognostic marker for BP therapy


    Source: Wang Y, Mao X, Liu Y, et al.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.